Scott A Rogers
Examiner (ID: 17114, Phone: (571)272-7467 , Office: P/2673 )
Most Active Art Unit | 2625 |
Art Unit(s) | 2724, 2626, 2106, 2625, 2721, 2853, 2673, 2624, 2672, 2627, 2899, 2108, 2681, 2612, 2616 |
Total Applications | 3003 |
Issued Applications | 2708 |
Pending Applications | 113 |
Abandoned Applications | 182 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18970441
[patent_doc_number] => 20240050533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => ORAL OCTREOTIDE THERAPY IN COMBINATION WITH DIGOXIN OR LISINOPRIL
[patent_app_type] => utility
[patent_app_number] => 18/335673
[patent_app_country] => US
[patent_app_date] => 2023-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10881
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335673
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/335673 | ORAL OCTREOTIDE THERAPY IN COMBINATION WITH DIGOXIN OR LISINOPRIL | Jun 14, 2023 | |
Array
(
[id] => 18692586
[patent_doc_number] => 20230322888
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/332690
[patent_app_country] => US
[patent_app_date] => 2023-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26404
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18332690
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/332690 | GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF | Jun 8, 2023 | Pending |
Array
(
[id] => 18842588
[patent_doc_number] => 20230404992
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MUSSEL ADHESIVE PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/310020
[patent_app_country] => US
[patent_app_date] => 2023-05-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18310020
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/310020 | TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MUSSEL ADHESIVE PROTEINS | Apr 30, 2023 | Pending |
Array
(
[id] => 18752317
[patent_doc_number] => 20230355541
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => ENZYMATICALLY CLEAVABLE SELF-ASSEMBLED NANOPARTICLES FOR MORPHOGEN DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/308810
[patent_app_country] => US
[patent_app_date] => 2023-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9414
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18308810
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/308810 | ENZYMATICALLY CLEAVABLE SELF-ASSEMBLED NANOPARTICLES FOR MORPHOGEN DELIVERY | Apr 27, 2023 | Pending |
Array
(
[id] => 18901394
[patent_doc_number] => 20240016879
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/303346
[patent_app_country] => US
[patent_app_date] => 2023-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8001
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303346
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/303346 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Apr 18, 2023 | Pending |
Array
(
[id] => 18550840
[patent_doc_number] => 20230248840
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/302655
[patent_app_country] => US
[patent_app_date] => 2023-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20628
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18302655
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/302655 | ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF | Apr 17, 2023 | Pending |
Array
(
[id] => 18922961
[patent_doc_number] => 20240025965
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => INTEGRIN BINDING PEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/295068
[patent_app_country] => US
[patent_app_date] => 2023-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21499
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18295068
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/295068 | INTEGRIN BINDING PEPTIDES AND USES THEREOF | Apr 2, 2023 | Pending |
Array
(
[id] => 18707612
[patent_doc_number] => 20230330189
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => ACYLATED GLP-1 DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 18/186069
[patent_app_country] => US
[patent_app_date] => 2023-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11963
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18186069
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/186069 | ACYLATED GLP-1 DERIVATIVE | Mar 16, 2023 | Pending |
Array
(
[id] => 18902728
[patent_doc_number] => 20240018213
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => MODULATORS OF NOTCH SIGNALING AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/167121
[patent_app_country] => US
[patent_app_date] => 2023-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33756
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -128
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18167121
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/167121 | MODULATORS OF NOTCH SIGNALING AND METHODS OF USE THEREOF | Feb 9, 2023 | Pending |
Array
(
[id] => 18404424
[patent_doc_number] => 20230165774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => Skin Care Composition and Method of Using the Same
[patent_app_type] => utility
[patent_app_number] => 18/149728
[patent_app_country] => US
[patent_app_date] => 2023-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7561
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18149728
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/149728 | Skin care composition and method of using the same | Jan 3, 2023 | Issued |
Array
(
[id] => 18779111
[patent_doc_number] => 11820804
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-21
[patent_title] => Peptide-based inhibitors of growth hormone action and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/051615
[patent_app_country] => US
[patent_app_date] => 2022-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 14
[patent_no_of_words] => 10775
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051615
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/051615 | Peptide-based inhibitors of growth hormone action and methods of use thereof | Oct 31, 2022 | Issued |
Array
(
[id] => 18404581
[patent_doc_number] => 20230165932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => PCSK9 ANTAGONIST COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/051250
[patent_app_country] => US
[patent_app_date] => 2022-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38171
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051250
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/051250 | PCSK9 ANTAGONIST COMPOUNDS | Oct 30, 2022 | Pending |
Array
(
[id] => 19425074
[patent_doc_number] => 12084477
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => Protein pores
[patent_app_type] => utility
[patent_app_number] => 17/933061
[patent_app_country] => US
[patent_app_date] => 2022-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 80
[patent_no_of_words] => 48677
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933061
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/933061 | Protein pores | Sep 15, 2022 | Issued |
Array
(
[id] => 18223917
[patent_doc_number] => 20230062911
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND/OR AMELIORATING CHEMOTHERAPY-INDUCED PREMATURE OVARIAN FAILURE (POF)
[patent_app_type] => utility
[patent_app_number] => 17/901950
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13368
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17901950
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/901950 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, AND/OR AMELIORATING CHEMOTHERAPY-INDUCED PREMATURE OVARIAN FAILURE (POF) | Sep 1, 2022 | Pending |
Array
(
[id] => 18628198
[patent_doc_number] => 20230287047
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4
[patent_app_type] => utility
[patent_app_number] => 17/820286
[patent_app_country] => US
[patent_app_date] => 2022-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820286
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820286 | Bicyclic peptide ligands specific for nectin-4 | Aug 16, 2022 | Issued |
Array
(
[id] => 18817490
[patent_doc_number] => 20230391830
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS
[patent_app_type] => utility
[patent_app_number] => 17/888252
[patent_app_country] => US
[patent_app_date] => 2022-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17888252
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/888252 | CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS | Aug 14, 2022 | Pending |
Array
(
[id] => 19338579
[patent_doc_number] => 12048750
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Tissue-homing peptide conjugates and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/888072
[patent_app_country] => US
[patent_app_date] => 2022-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 57
[patent_figures_cnt] => 80
[patent_no_of_words] => 146873
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17888072
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/888072 | Tissue-homing peptide conjugates and methods of use thereof | Aug 14, 2022 | Issued |
Array
(
[id] => 18077359
[patent_doc_number] => 20220402971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => KRAS-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF MAKING AND USING
[patent_app_type] => utility
[patent_app_number] => 17/815805
[patent_app_country] => US
[patent_app_date] => 2022-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10771
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815805
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/815805 | KRAS-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF MAKING AND USING | Jul 27, 2022 | Pending |
Array
(
[id] => 18075856
[patent_doc_number] => 20220401468
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => Heparanase Inhibitor as Anti-Viral and Immunomodulatory Therapy
[patent_app_type] => utility
[patent_app_number] => 17/841655
[patent_app_country] => US
[patent_app_date] => 2022-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19006
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841655
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/841655 | Heparanase Inhibitor as Anti-Viral and Immunomodulatory Therapy | Jun 14, 2022 | Pending |
Array
(
[id] => 18003572
[patent_doc_number] => 20220362338
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
[patent_app_type] => utility
[patent_app_number] => 17/840602
[patent_app_country] => US
[patent_app_date] => 2022-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11401
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17840602
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/840602 | TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | Jun 13, 2022 | Abandoned |